Investigators at Weill Cornell Medicine have developed a versatile and non-toxic technology for controlling the activity of ...

Developers of biosimilars, medicines that are near-identical copies of biologic drugs, will no longer be required to conduct clinical trials to prove effectiveness.

By partnering with Surescripts, life sciences companies can tap into a vast network of health plans and pharmacy benefit ...